Thymidylate Synthase Antibody 35-5800 from Thermo Fisher Scientific

81 Wyman Street

Waltham, MA 02451

United States

Phone: 800-678-5599
Fax: 800-331-2286

(3) Molecular profiling in gastric cancer: examining potential targets for chemotherapyJournal of surgical oncologySeptember 1, 2014Miura JT, Johnston FM, Thomas J, George B, Eastwood D, Tsai S, Christians KK, Turaga KK, Gamblin TC.

(4) The poison oligonucleotide F10 is highly effective against acute lymphoblastic leukemia while sparing normal hematopoietic cellsOncotargetJune 30, 2014Pardee TS, Stadelman K, Jennings-Gee J, Caudell DL, Gmeiner WH.membrane (Millipore, Billerica, MA). Antibodies against p53 (IMX25, 1:1000; Leica Microsystems), TS (#35-5800, 1:1000; Invitrogen), Topoisomerase I (556597, 1:2000; BD Pharmingen), Caspase 3 (9662, 1:2000; Cell Signalling

(5) Thymidylate synthase and folyl-polyglutamate synthase are not clinically useful markers of response to pemetrexed in patients with malignant pleural mesotheliomaJournal of thoracic oncology : official publication of the International Association for the Study of Lung CancerApril 1, 2013Lustgarten DE, Deshpande C, Aggarwal C, Wang LC, Saloura V, Vachani A, Wang LP, Litzky L, Feldman M, Creaney J, et al.

(6) Translational repression of thymidylate synthase by targeting its mRNANucleic acids researchApril 1, 2013Garg D, Beribisky AV, Ponterini G, Ligabue A, Marverti G, Martello A, Costi MP, Sattler M, Wade RC.

(7) Biological evaluation of MR36, a novel non-polyglutamatable thymidylate synthase inhibitor that blocks cell cycle progression in melanoma cell linesInvestigational new drugsAugust 1, 2012Giudice S, Benassi L, Bertazzoni G, Veratti E, Morini D, Azzoni P, Costi MP, Venturelli A, Pirondi S, Seidenari S, et al.

(9) Phase 2 trial of oxaliplatin and pemetrexed as an induction regimen in locally advanced head and neck cancerCancerFebruary 15, 2012Gilbert J, Murphy B, Dietrich MS, Henry E, Jordan R, Counsell A, Wirth P, Yarbrough WG, Slebos RJ, Chung CH.

(12) Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapyJournal of clinical oncology : official journal of the American Society of Clinical OncologyMarch 20, 2010Righi L, Papotti MG, Ceppi P, Billè A, Bacillo E, Molinaro L, Ruffini E, Scagliotti GV, Selvaggi G.

(14) beta-Tubulin-II expression strongly predicts outcome in patients receiving induction chemotherapy for locally advanced squamous carcinoma of the head and neck: a companion analysis of the TAX 324 trialJournal of clinical oncology : official journal of the American Society of Clinical OncologyDecember 20, 2009Cullen KJ, Schumaker L, Nikitakis N, Goloubeva O, Tan M, Sarlis NJ, Haddad RI, Posner MR.

(15) Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRCJournal of the National Cancer InstituteMarch 19, 2008Di Costanzo F, Gasperoni S, Manzione L, Bisagni G, Labianca R, Bravi S, Cortesi E, Carlini P, Bracci R, Tomao S, et al.

(16) ERCC1 predicting chemoradiation resistance and poor outcome in oesophageal cancerEur J CancerJanuary 1, 2008Kim MK, Cho KJ, Kwon GY, Park SI, Kim YH, Kim JH, Song HY, Shin JH, Jung HY, Lee GH, et al.

(18) High thymidylate synthase expression in colorectal cancer with microsatellite instability: implications for chemotherapeutic strategiesClinical cancer research : an official journal of the American Association for Cancer ResearchJune 1, 2005Ricciardiello L, Ceccarelli C, Angiolini G, Pariali M, Chieco P, Paterini P, Biasco G, Martinelli GN, Roda E, Bazzoli F.

IHC